Cost of treating chronic hepatitis B: Comparison of current treatment guidelines

Table 3 Calculated costs (in Australian dollars) of implementing a program of chronic hepatitis B management in hepatitis B e antigen-negative patients according to the B positive algorithms and published hepatitis B treatment guidelines, n (%)

Discounted costs of management strategies	B positive	Modified B positive	APASL	EASL, United States experts	AASLD
Cost/QALY (discounted)	13 465	15 770	11 746	19 622	8867
Total program cost (discounted)	13 979 224	16 372 320	12 194 905	20 371 117	9 205 680
Cost components
Initial CHB screening cost	767 728 (5.5)	800 792 (4.9)	755 971 (6.2)	845 613 (4.2)	720 357 (7.8)
Drug treatment costs	9 347 662 (66.9)	11 493 535 (70.2)	7 360 940 (60.4)	15 447 510 (75.8)	4 951 419 (53.8)
CHB surveillance costs	2 827 093 (20.2)	2 866 053 (17.5)	2 866 053 (23.5)	2 866 053 (14.1)	2 767 073 (30.1)
HCC surveillance costs	917 783 (6.6)	1 092 983 (6.7)	1 092 983 (9.0)	1 092 983 (5.4)	647 874 (7.0)
Total cost per person in the program	9634	11 283	8404	14 039	6344
% change with equivalent unit costs/QALY	100	117	87	146	66

Tabulates the costs of chronic hepatitis B screening, surveillance and treatment as per Australian, Asia-Pacific, United States and European treatment guidelines scenarios. Costs are discounted by 5% and calculated in Australian dollars (AUD). EASL: European Associations for the Study of Liver Disease; APASL: Asia-Pacific Associations for the Study of Liver Disease; AASLD: American Associations for the Study of Liver Disease; HCC: Hepatocellular cancer; CHB: Chronic hepatitis B; QALY: Quality-adjusted life year.